Pers nieuws
Pers nieuws
Scientists unravel genetic evolution of individual tumor cells
The research group of Hugo Snippert, Oncode Investigator at the Center of Molecular Medicine at UMC Utrecht, report the first detailed insights into the pace and patterns by which genetic alterations are generated by tumors.
Read moreDENSE research wins Science and Innovation Award 2021
Breast cancer in women with dense mammary gland tissue is better detectable with an MRI
Read moreJun 29: Psoriasis and psoriatic arthritis fall within a spectrum of one single disease
Psoriasis and psoriatic arthritis (PsA) have a predominantly shared genetic background and overlapping immunologic and proteomic signature.
Read moreBasic research at UMC Utrecht contributes to candidate immunotherapeutic drug
Investigators at UMC Utrecht and biopharmaceutical company NextCure have published preclinical data on the LAIR family of molecules.
Read moreResearch into plastic in the human body
Small plastic particles are found everywhere in our environment. We ingest them through the food we eat, the water we drink or the air we breathe.
Read moreVitamin K in micelles as an alternative to injections
Oral administration to prevent brain hemorrhage in infants with impaired fat intake
Read moreLaunch of European research into radiotherapy for cardiac arrhythmias
STOPSTORM is a resereach project that will be researching the use of radiotherapy in treating cardiac arrhythmias.
Read moreTwo grants (NWO and ZonMW) for Utrecht researchers
Utrecht researchers Magdalena Harakalova, Frank van Steenbeek, Folkert Asselbergs and Jeroen Bakkers have obtained prestigious funding to further build infrastructure on genetic cardiomyopathies (severe diseases of the cardiac muscle).
Read moreInaugural lecture by Seye Abimbola about health inequality
“My work as holder of the Prince Claus Chair has broadened my focus”
Read moreNovel technology for improved detection of clinically relevant chromosomal rearrangements in tumors
Researchers from the group of Wouter de Laat (UMC Utrecht and Hubrecht Institute), in collaboration with biotech company Cergentis and lymphoma experts of 5 Dutch hospitals, developed a novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors.
Read more